


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nirogacestat for treating desmoid tumours ID6453

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	Submit of appeal)
Company	General
SpringWorks Therapeutics	All Wales Therapeutics and Toxicology
(Nirogacestat)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Beacon	Wales
Black Health Agency for Equality	British National Formulary
Cancer 52	Care Quality Commission
Cancer Black Care	Department of Health - Northern Ireland
Desmoid Aid UK	Healthcare Improvement Scotland
Desmoid Fibromatosis Patients &	Medicines and Healthcare products
Caregivers UK	Regulatory Agency
Helen Rollason Cancer Charity	National Association of Primary Care
Independent Cancer Patients Voice	National Pharmacy Association
Macmillan Cancer Support	NHS Confederation
Maggie's Centres	NHS Wales Joint Commissioning
Marie Curie	Committee
Tenovus Cancer Care	Scottish Medicines Consortium
Sarcoma UK	Welsh Government
South Asian Health Foundation	Descible comperator companies
Specialised Healthcare Alliance	Possible comparator companies
Healtheare professional groups	Amarox (imatinib mesilate)Bayer (sorafenib tosilate)
Healthcare professional groupsAssociation of Cancer Physicians	Bayer (soratenib tosilate)Cipla (imatinib mesilate)
 Association of Cancer Physicians Association of Upper Gastrointestinal 	Dr Reddy's Laboratories (imatinib
Surgeons of Great Britain and Ireland	mesilate)
British Association of Surgical	Grindeks Kalceks (imatinib mesilate)
Oncology	Novartis Pharmaceuticals (pazopanib)
British Oncology Pharmacy	hydrochloride, imatinib mesilate)
Association	Orion Pharma (imatinib mesilate)
British Psychosocial Oncology Society	Sandoz (sorafenib tosilate, imatinib
British Sarcoma Group	mesilate)
Cancer Research UK	Thornton & Ross (sorafenib tosilate)
Royal College of General Practitioners	Zentiva (sorafenib tosilate)
Royal College of Nursing	,
Royal College of Pathologists	Relevant research groups
Royal College of Physicians	Cochrane Gut



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research
Others Department of Health and Social Care NHS England	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Provisional stakeholder list for the evaluation of nirogacestat for treating desmoid tumours ID6453 Issue date: July 2025





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.